Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism

Crizotinib is a standard treatment for advanced ALK‐positive non‐small‐cell lung cancer (NSCLC). We undertook this study to investigate the pharmacokinetics of crizotinib and clinical and pharmacogenomic factors that may increase the risk of adverse events (AEs). We defined clinically significant AE...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Hamada, Akinobu, Mizugaki, Hidenori, Aikawa, Hiroaki, Hata, Toshiyuki, Horinouchi, Hidehito, Kanda, Shintaro, Goto, Yasushi, Itahashi, Kota, Nokihara, Hiroshi, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982581/
https://www.ncbi.nlm.nih.gov/pubmed/27270784
http://dx.doi.org/10.1111/cas.12983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982581/
https://www.ncbi.nlm.nih.gov/pubmed/27270784
http://dx.doi.org/10.1111/cas.12983

Ejemplares similares